Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is an SEC Form 8-K, specifically Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing the proposals voted on at the 2026 Annual Meeting and the tabulated results. This constitutes an official disclosure of shareholder voting results, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-22 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-19 English
8-K
Regulatory Filings Classification · 85% confidence The document is a United States SEC Form 8-K “Current Report” filed under the Securities Exchange Act of 1934, describing Item 1.02 Termination of a Material Definitive Agreement (an at-the-market offering agreement). There is no specific category for Form 8-K filings in the taxonomy; these general compliance reports fall into the Regulatory Filings catch-all category.
2026-05-14 English
424B5
Share Issue/Capital Change Classification · 84% confidence The document is a Form 424B5 prospectus supplement under Rule 424(b)(5), amending a registration statement on Form S-3 for an at-the-market common stock offering, detailing shares sold to date, terminating the sales agreement, and reporting capital structure changes. This is an announcement and update of a new share issuance and related offering termination, fitting the “Share Issue/Capital Change” category.
2026-05-14 English
10-Q - MAIA Biotechnology, Inc. (0001878313) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about activating a clinical trial site, which is an event update rather than a financial report or detailed management discussion. There are no financial statements or detailed financial data included. The document is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial or governance report. It is a regulatory filing to inform the market of a significant event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 6285 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2026-04-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.